Literature DB >> 26002023

Syndesmophyte growth in ankylosing spondylitis.

Sovira Tan1, Runsheng Wang, Michael M Ward.   

Abstract

PURPOSE OF REVIEW: Syndesmophytes are characteristic components of the spine disorder of ankylosing spondylitis. Understanding their growth may reveal insights to pathogenesis and potential treatment. We review recent studies on rates of development of syndesmophytes, patient characteristics associated with more rapid syndesmophyte growth, local vertebral abnormalities that precede syndesmophytes, systemic biomarkers of syndesmophytes, and studies of medications. RECENT
FINDINGS: New syndesmophytes develop in one-third of patients over 2 years. Consistent clinical predictors are male sex, elevated serum C-reactive protein levels, and preexisting syndesmophytes. Concomitant vertebral inflammation and fat dysplasia on MRI predict future syndesmophytes at the same vertebral location, but most syndesmophytes do not have recognized antecedents. Associations with serum levels of Wingless pathway proteins are inconsistent, as are the results of observational studies of tumor necrosis factor-alpha inhibitors.
SUMMARY: Although there is better understanding of the frequency of syndesmophyte development, the pathogenesis of syndesmophytes remains unclear.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26002023      PMCID: PMC4478446          DOI: 10.1097/BOR.0000000000000179

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  31 in total

1.  Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study.

Authors:  Astrid van Tubergen; Sofia Ramiro; Désirée van der Heijde; Maxime Dougados; Herman Mielants; Robert Landewé
Journal:  Ann Rheum Dis       Date:  2011-10-11       Impact factor: 19.103

2.  Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis.

Authors:  Denis Poddubnyy; Kristina Conrad; Hildrun Haibel; Uta Syrbe; Heiner Appel; Jürgen Braun; Martin Rudwaleit; Joachim Sieper
Journal:  Ann Rheum Dis       Date:  2013-08-16       Impact factor: 19.103

3.  Brief report: erosions and sclerosis on radiographs precede the subsequent development of syndesmophytes at the same site: a twelve-year prospective followup of patients with ankylosing spondylitis.

Authors:  Sofia Ramiro; Astrid van Tubergen; Désirée van der Heijde; Carmen Stolwijk; Gideon Bookelman; Maxime Dougados; Filip van den Bosch; Robert B M Landewé
Journal:  Arthritis Rheumatol       Date:  2014-10       Impact factor: 10.995

4.  Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography.

Authors:  X Baraliakos; F Heldmann; J Callhoff; J Listing; T Appelboom; J Brandt; F Van den Bosch; M Breban; Gr Burmester; M Dougados; P Emery; H Gaston; M Grunke; I E Van Der Horst-Bruinsma; R Landewé; M Leirisalo-Repo; J Sieper; K De Vlam; D Pappas; U Kiltz; D Van Der Heijde; J Braun
Journal:  Ann Rheum Dis       Date:  2013-07-14       Impact factor: 19.103

5.  Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort.

Authors:  Sofia Ramiro; Désirée van der Heijde; Astrid van Tubergen; Carmen Stolwijk; Maxime Dougados; Filip van den Bosch; Robert Landewé
Journal:  Ann Rheum Dis       Date:  2014-05-07       Impact factor: 19.103

6.  Biomarkers of bone metabolism in ankylosing spondylitis in relation to osteoproliferation and osteoporosis.

Authors:  Eva Klingberg; Merja Nurkkala; Hans Carlsten; Helena Forsblad-d'Elia
Journal:  J Rheumatol       Date:  2014-07       Impact factor: 4.666

7.  Quantitative measurement of syndesmophyte volume and height in ankylosing spondylitis using CT.

Authors:  Sovira Tan; Jianhua Yao; John A Flynn; Lawrence Yao; Michael M Ward
Journal:  Ann Rheum Dis       Date:  2013-01-23       Impact factor: 19.103

8.  Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis.

Authors:  Xenofon Baraliakos; Hildrun Haibel; Joachim Listing; Joachim Sieper; Jürgen Braun
Journal:  Ann Rheum Dis       Date:  2013-03-16       Impact factor: 19.103

9.  Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis.

Authors:  Dimitrios Daoussis; Stamatis-Nick C Liossis; Elena E Solomou; Anastasia Tsanaktsi; Konstadina Bounia; Maria Karampetsou; Georgios Yiannopoulos; Andrew P Andonopoulos
Journal:  Arthritis Rheum       Date:  2010-01

10.  The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial.

Authors:  Jürgen Braun; Xenofon Baraliakos; Kay-Geert A Hermann; Atul Deodhar; Désirée van der Heijde; Robert Inman; Anna Beutler; Yiying Zhou; Stephen Xu; Benjamin Hsu
Journal:  Ann Rheum Dis       Date:  2013-05-03       Impact factor: 19.103

View more
  14 in total

1.  Baseline increased 18F-fluoride uptake lesions at vertebral corners on positron emission tomography predict new syndesmophyte development in ankylosing spondylitis: a 2-year longitudinal study.

Authors:  Eun-Kyoung Park; Kyoungjune Pak; Ji-Heh Park; Keunyoung Kim; Seong-Jang Kim; In-Joo Kim; Geun-Tae Kim; Seung-Geun Lee
Journal:  Rheumatol Int       Date:  2017-02-02       Impact factor: 2.631

2.  Role of vertebral corner inflammation and fat deposition on MRI on syndesmophyte development detected on whole spine low-dose CT scan in radiographic axial spondyloarthritis.

Authors:  Rosalinde Stal; Xenofon Baraliakos; Désirée van der Heijde; Floris van Gaalen; Sofia Ramiro; Rosaline van den Berg; Monique Reijnierse; Juergen Braun; Robert Landewé; Alexandre Sepriano
Journal:  RMD Open       Date:  2022-07

Review 3.  Inflammasomes and the IL-1 Family in Bone Homeostasis and Disease.

Authors:  Hsu-Wen Tseng; Selwin Gabriel Samuel; Kate Schroder; Jean-Pierre Lévesque; Kylie A Alexander
Journal:  Curr Osteoporos Rep       Date:  2022-05-14       Impact factor: 5.163

4.  Recommendation for the Management of Spondyloarthritis Patients in Kuwait.

Authors:  Yaser Ali; Fatemah Abutiban; Adel Alawadhi; Ali AlDei; Ahmad Alenizi; Hebah Alhajeri; Adeeba Al-Herz; Waleed Alkandari; Ahmad Dehrab; Eman Hasan; Sawsan Hayat; Aqeel Ghanem; Khulood Saleh; Xenofon Baraliakos
Journal:  Open Access Rheumatol       Date:  2020-08-12

5.  Disease progression associated with low bone mass in axial spondyloarthropathy patients.

Authors:  De Hao Liu; Juan Chen; Xiong Jie Zhuang; Li Chun Chen
Journal:  Arch Osteoporos       Date:  2021-04-08       Impact factor: 2.617

Review 6.  Bone Involvement in Patients with Spondyloarthropathies.

Authors:  Willem Lems; Corinne Miceli-Richard; Judith Haschka; Andrea Giusti; Gitte Lund Chistensen; Roland Kocijan; Nicolas Rosine; Niklas Rye Jørgensen; Gerolamo Bianchi; Christian Roux
Journal:  Calcif Tissue Int       Date:  2022-01-23       Impact factor: 4.333

7.  Degenerative and Inflammatory Osteoproliferations in Lumbar Radiographs in Psoriatic Arthritis Patients.

Authors:  Gizem Ayan; Abdurrahman Sadic; Levent Kilic; Umut Kalyoncu
Journal:  J Clin Med       Date:  2022-04-03       Impact factor: 4.241

8.  Alcohol consumption as a predictor of the progression of spinal structural damage in axial spondyloarthritis: data from the Catholic Axial Spondyloarthritis COhort (CASCO).

Authors:  Hong Ki Min; Jennifer Lee; Ji Hyeon Ju; Sung-Hwan Park; Seung-Ki Kwok
Journal:  Arthritis Res Ther       Date:  2019-08-14       Impact factor: 5.156

9.  Small leucine rich proteoglycans, a novel link to osteoclastogenesis.

Authors:  Vardit Kram; Tina M Kilts; Nisan Bhattacharyya; Li Li; Marian F Young
Journal:  Sci Rep       Date:  2017-10-03       Impact factor: 4.379

10.  The shape language in application to the diagnosis of cervical vertebrae pathology.

Authors:  Marzena Bielecka; Rafał Obuchowicz; Mariusz Korkosz
Journal:  PLoS One       Date:  2018-10-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.